Log In Sign up
The largest database of trusted experimental protocols
> Procedures > Therapeutic or Preventive Procedure > Lumpectomy

Lumpectomy

Lumpectomy is a surgical procedure in which a small portion of breast tissue containing a tumor or abnormality is removed, while leaving the majority of the breast intact.
This breast-conserving surgery is often used as an alternative to mastectomy for the treatment of early-stage breast cancer.
Lumpectomy may be followed by radiation therapy to help reduce the risk of cancer recurrence.
The goal of this procedure is to remove the cancerous or abnormal area while preserving the shape and appearance of the breast.
Lumpectomy is considered a less invasive option compared to mastectomy and can help maintain a pateitnt's quality of life after treatment.

Most cited protocols related to «Lumpectomy»

1
Breast Cancer Surgery Timing Analysis
Cited 17 times
The National Cancer Database14 (link) cohort included those having noninflammatory, invasive, nonmetastatic breast cancer, having surgical treatment as their first modality ≤6 months after their diagnosis date. Patients were included if breast cancer was their first and only malignancy, and if diagnosis and treatment (all or part) was at the reporting facility. Patients without lymph node surgery or whose staging, diagnosis method, or treatment order was unknown were excluded. The NCDB does not provide a diagnosis date, but after 2002 recorded the length of the interval between diagnosis and surgery. This interval length was present for cases diagnosed from 2003 onward. The NCDB requires follow-up of >5 years, so the cohort only included cases from 2003–2005 with follow-up through 2010.
The NCDB contains the most extensive surgery (e.g. a lumpectomy followed by mastectomy lists the patient as having a mastectomy). The NCDB also contains interval lengths from diagnosis to first surgery and from diagnosis to definitive surgery, to determine if the patient underwent >1 procedure. We excluded patients with >1 breast surgery to ensure capture of therapeutic surgery and to eliminate possible confounding excisional biopsies, ensuring that the analysis evaluated the time to therapeutic surgery. Patients receiving neoadjuvant chemotherapy were excluded, and chemotherapy and radiotherapy use were defined as being administered if given ≤1 year after surgery. Missing covariate data is listed in eTable 2.
Adjustments were made for age, sex, race, income, education, size of metropolitan area, geographical region, year of diagnosis, Charlson-Deyo comorbidity score, histology, grade, tumor size, surgical margins, number of nodes examined, number of nodes positive, AJCC stage, surgery type, chemotherapy, radiotherapy, endocrine therapy, facility type, distance to facility, class of case, and insurance type, via propensity score based weighting.
Bleicher R.J., Ruth K., Sigurdson E.R., Beck J.R., Ross E., Wong Y.N., Patel S.A., Boraas M., Chang E.I., Topham N.S, & Egleston B.L. (2016). Time to Surgery and Breast Cancer Survival in the United States. JAMA oncology, 2(3), 330-339.
Publication 2015
Biopsy Diagnosis Lumpectomy Malignant Neoplasm of Breast Malignant Neoplasms Mastectomy Neoadjuvant Chemotherapy Neoplasms Nodes, Lymph Operative Surgical Procedures Patients Pharmacotherapy Radiotherapy Surgical Margins System, Endocrine Therapeutics Thoracic Surgical Procedures
2
Optimal Lymph Flow for Breast Cancer
Cited 10 times
We recruited women who were over age 21, first time diagnosis of breast cancer (Stage I-III), and scheduled for surgical treatment, including lumpectomy or mastectomy, sentinel lymph node biopsy (SLNB) or axillary lymph node dissection ALND). Women with metastatic cancer (Stage IV), prior history of breast cancer and lymphedema, and bilateral breast cancer were excluded. Between April 2010 and June 2012, we prospectively enrolled 140 women and followed the participants for 12 months after surgery. All the participants received the The-Optimal-Lymph-Flow program.
Fu M.R., Axelrod D., Guth A.A., Cartwright F., Qiu Z., Goldberg J.D., Kim J., Scagliola J., Kleinman R, & Haber J. (2014). Proactive Approach to Lymphedema Risk Reduction: A Prospective Study. Annals of surgical oncology, 21(11), 3481-3489.
Publication 2014
Axilla Diagnosis Lumpectomy Lymph Lymphedema Lymph Node Dissection Malignant Neoplasm of Breast Mastectomy Neoplasm Metastasis Operative Surgical Procedures Sentinel Lymph Node Biopsy Woman
3
Randomized Trial of SLND and ALND for Breast Cancer
Cited 10 times
All participants were women at least 18 years of age with clinical T1 or T2 N0 M0 breast cancer treated with SLND and breast-conserving therapy as previously described.9 (link) Lumpectomy margins were required to be negative for study participation. Planned mastectomy was not permitted. Patients must have undergone SLND within 60 days of the diagnosis of invasive breast carcinoma and have an ECOG/Zubrod status less than or equal to 2. A SN containing metastatic breast cancer must have been identified by frozen section, touch preparation or permanent section. Patients with metastatic breast cancer to the SN identified by immunohistochemical staining (IHC) were not eligible. Patients were randomized to completion ALND or no ALND and no further axillary-specific therapy, specifically no third field nodal irradiation. All patients received opposing tangential field whole breast irradiation. ALND was defined as an anatomic Level I and II dissection with at least 10 nodes removed. Adjuvant systemic therapy was determined by physician and patient selection. For patients randomized to completion ALND, the operation must have been performed within 42 days of the SLND. Pregnant or lactating patients were excluded as were patients treated with neoadjuvant chemo- or hormonal therapy. In addition, patients with bilateral breast cancer were excluded as were those with multicentric disease, a history of ipsilateral axillary surgery, pre-pectoral implants, or those with medical contraindications to ALND. Patients with matted nodes or gross extranodal disease at the time of SLND were excluded as were patients with three or more involved SNs.
Participants entered the study through two pathways, the most common of which was randomization post-SLND when the final histopathologic results of examination of the SN were known. However, some patients were pre-registered before SLND and then randomly assigned to a treatment arm intraoperatively by an interactive automated telephone system when frozen section or touch preparation analysis documented a tumor-involved SN. Although some of these patients were subsequently found to have three or more tumor-involved SNs, they were included in the analyses. All patients gave written informed consent, and all institutions obtained approval by their institutional review board. There were 165 investigators and 177 institutions participating in this study. Figure 1 illustrates the study schema.
Giuliano A.E., McCall L., Beitsch P., Whitworth P.W., Blumencranz P., Leitch A.M., Saha S., Hunt K.K., Morrow M, & Ballman K. (2010). Locoregional Recurrence after Sentinel Lymph Node Dissection with or without Axillary Dissection in Patients with Sentinel Lymph Node Metastases: The American College of Surgeons Oncology Group Z0011 Randomized Trial. Annals of surgery, 252(3), 426-433.
Publication 2010
Axilla Breast Breast Carcinoma Cryoultramicrotomy Diagnosis Dissection Electrocorticography Ethics Committees, Research Lumpectomy Malignant Neoplasm of Breast Mastectomy Neoadjuvant Therapy Neoplasm Metastasis Neoplasms Operative Surgical Procedures Patients Pharmaceutical Adjuvants Physicians Radiotherapy Touch Woman
4
Longitudinal Outcomes of Breast Cancer Surgery
Cited 7 times
Characteristics of the participants were summarized using descriptive statistics (means, standard deviations for continuous variables and frequency distributions and proportions for qualitative variables). Distributions of baseline patient demographic and clinical characteristics were compared for patients with SLNB and ALND using Chi-Squared tests for contingency tables and one-way analysis of variance for continuous variables. All statistical tests were conducted at the 0.05 significance level (2-sided) and 95% confidence intervals (CI) were provided for estimates.
Mixed effects regression models were used with subject specific intercepts (and slopes if appropriate) with fixed effects of time to evaluate the changes from baseline in outcome measures of LV and BMI over time. Participants were included as a random effect to allow for the incorporation within a subject as well as missing data over time [23 ]. Correlations were examined to identify potential interactions and redundancies among variables. Predictive covariates (such as age, ethnicity, lumpectomy vs. mastectomy, SNLB vs. ALND) were included in the models.
Fu M.R., Axelrod D., Guth A.A., Cartwright F., Qiu Z., Goldberg J.D., Kim J., Scagliola J., Kleinman R, & Haber J. (2014). Proactive Approach to Lymphedema Risk Reduction: A Prospective Study. Annals of surgical oncology, 21(11), 3481-3489.
Publication 2014
Ethnicity Lumpectomy Mastectomy Patients
5
Longitudinal Assessment of Lymphedema in Breast Cancer
Cited 7 times
The study was designed to use prospective, repeated measures on 211 female participants newly-diagnosed with breast cancer. Participant recruitment and data collection took place at a Midwestern university-affiliated state cancer centre. Consent was obtained and the participants were then enrolled. They were assessed pre-and post-treatment, every three months for 12 months, then every six months thereafter, for a total of 30 months.
Two objective measurement techniques were used at each visit to quantify limb volume characteristics: circumferential measurement and infra-red perometery. Traditional anthropometric measurements recorded limb girth every 4cm on each arm using a non-stretch, flexible tape measure. Infra-red perometry (Perometer 400T/350S, Juzo, Cuyahoga Falls, OH) was used to record three-dimensional images of each limb, which were used to calculate limb volume. A detailed description of these techniques has been previously published (Armer and Stewart, 2005 ).
In addition to the two objective measures, one subjective analysis of LE symptoms was administered each visit through the LE and Breast Cancer Questionnaire (LBCQ) (Armer et al, 2003 (link)). The LBCQ, which has previously been validated, consists of 57 questions examining 19 signs and symptoms drawn from the literature and clinical observation (Armer et al, 2003 (link)). Based on these previous findings, self-report of heaviness or swelling ‘now’ or ‘in the past year’, was included as one definition for LE.
From those measurements, four criteria for identifying LE were used:

2cm circumferential change at any measured location

200ml perometry LVC of the affected arm

10% perometry LVC of the affected arm

Self-report of limb heaviness and swelling, either ‘now’ or ‘in the past year.’

The objective-based criteria for identifying LE (the first three items above) were based on change from baseline measurements and/or versus unaffected limb.
Certain participants met the definitions for LE before treatment at the baseline (pre-treatment) measurement for one or more of the four criteria used. Those participants were included in the study, but not for analysis in that particular criteria, resulting in different numbers of participants for a given criteria. For example, 16 of the 211 participants met the definition for LE at baseline based on the criteria of self-reported limb heaviness and swelling, resulting in 195 participants in the subsequent self-report analysis. Also, those participants who had both right and left limbs affected due to bilateral mastectomies, lumpectomies, or for prophylactic reasons at any point during the study, were not included for this analysis.
Armer J.M., Stewart B.R, & Shook R.P. (2009). 30-MONTH POST-BREAST CANCER TREATMENT LYMPHOEDEMA. Journal of lymphoedema, 4(1), 14-18.
Publication 2009
Condoms Lumpectomy Malignant Neoplasm of Breast Malignant Neoplasms Mastectomy Woman

Most recents protocols related to «Lumpectomy»

1
General Surgery Procedures during COVID-19
This cohort study was determined to be exempt from review and informed consent by the institutional review board of the Mayo Clinic, Rochester, Minnesota, owing to the use of deidentified data. The study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.
Adult patients (ie, patients aged ≥18 years) who underwent 1 of 16 commonly scheduled general surgery operations (minimally invasive colectomy for cancer, minimally invasive colectomy for benign disease, lumpectomy for breast cancer, mastectomy for breast cancer, minimally invasive adrenalectomy, thyroid lobectomy, total thyroidectomy, parathyroidectomy, minimally invasive inguinal hernia repair, open inguinal hernia repair, minimally invasive ventral hernia repair, open umbilical hernia repair, minimally invasive sleeve gastrectomy, minimally invasive gastric bypass, minimally invasive cholecystectomy, and minimally invasive fundoplication) from January 1, 2016, to December 31, 2019 (before COVID-19), and January 1 to December 31, 2020 (during the COVID-19 pandemic), were identified in the ACS-NSQIP database using Current Procedural Terminology codes (eTable 1 in Supplement 1). These 16 procedures were selected as they represented the most frequently performed general surgery operations identified by the surgical specialty variable within the ACS-NSQIP database and consisted of a variety of procedures. To limit case-mix variation over time, each procedure group was limited to a consistent set of diagnosis codes specific to that procedure, based on codes from the International Classification of Diseases, Ninth Revision, Clinical Modification, or the International Statistical Classification of Diseases, Tenth Revision, Clinical Modification (eTable 1 in Supplement 1). Patients with severe preoperative comorbidities that were likely to necessitate an inpatient stay (preoperative ventilator dependence, sepsis, septic shock, systemic inflammatory response syndrome, open and/or infected wound, acute renal failure, >4 U of red blood cell transfused within 72 hours prior to procedure, American Society of Anesthesiologists [ASA] class V, and disseminated cancer), and urgent or emergent operations were excluded from the analysis. Details regarding the number of hospitals participating in the ACS-NSQIP, the total number of cases submitted, the process for data collection, definitions of outcome variables, and procedures for ensuring the reliability of the data are described in the ACS-NSQIP Participant Use Data File user guide.10
Shariq O.A., Bews K.A., Etzioni D.A., Kendrick M.L., Habermann E.B, & Thiels C.A. (2023). Performance of General Surgical Procedures in Outpatient Settings Before and After Onset of the COVID-19 Pandemic. JAMA Network Open, 6(3), e231198.
Full text: Click here
Publication 2023
Adrenalectomy Adult Anesthesiologist Cholecystectomy Colectomy COVID 19 Diagnosis Dietary Supplements Erythrocytes Ethics Committees, Research Gastrectomy Gastric Bypass Hernia, Inguinal Herniorrhaphy Inpatient Kidney Failure, Acute Lumpectomy Malignant Neoplasm of Breast Malignant Neoplasms Mastectomy Nissen Operation Operative Surgical Procedures Parathyroidectomy Patients Septicemia Septic Shock Systemic Inflammatory Response Syndrome Thyroidectomy Thyroid Gland Umbilicus Ventral Hernia Wound Infection
2
Lymphedema Patient Characteristics and Treatment
Baseline characteristics included patient (age, height, weight, dominant side, relationship status, smoking status, alcohol consumption, lymphedema duration, and current lymphedema treatment) and treatment (type of surgery, mastectomy or lumpectomy, laterality of surgery, number of lymph nodes removed, and type of oncologic treatment) characteristics.
Gulmark Hansen F.C., Jørgensen M.G, & Sørensen J.A. (2023). Treatment of Breast Cancer-Related Lymphedema With Topical Tacrolimus: A Prospective, Open-Label, Single-Arm, Phase II Pilot Trial. Journal of Breast Cancer, 26(1), 46-59.
Publication 2023
Functional Laterality Lumpectomy Lymphedema Mastectomy Neoplasms Nodes, Lymph Operative Surgical Procedures Patients
3
Breast Cancer Treatment Quality of Life
The BREAST-Q scale measurement was the tool chosen to support the data collection following the OECD guidelines for the international data collection on breast cancer PROMs [11 ]. The BREAST-Q scale was developed and validated to assess the impact and effectiveness of breast surgery to treat breast cancer from the perspective of the patient themselves and is an important measure of the health-related quality of life [15 (link)].
The BREAST-Q scale satisfaction with breast following BCT (lumpectomy) module has 11 items over four response hypotheses (1—very dissatisfied; 2—somewhat dissatisfied; 3—somewhat satisfied; 4—very satisfied). These items cover breast appearance in terms of size, symmetry, softness, implant placement, cleavage, and satisfaction with breasts in relation to how a bra fits and how the breasts look when clothed or unclothed. Instructions were given to the participant to fill out the questionnaire as follows:
“The following questions are about your breasts and your breast cancer treatment (by treatment, we mean lumpectomy with or without radiation). If you have had a lumpectomy, answer these questions thinking of the breast you are least satisfied with. With your breasts in mind, in the past, how satisfied or dissatisfied have you been with (…)”.
The translation and back-translation to Portuguese were carried out with the involvement of three researchers and the advice of three medical specialists in the field of breast cancer. The Portuguese version of the instrument showed excellent internal consistency (alpha = 0.93).
To complement data on BREAST-Q, the study also collected data on a complementary variable: the reduced version of the 6-item WHO QOL-BREF scale (WHOQOL) validated by Gaspar (2021) was used to measure the quality of life, with a good internal consistency (alpha = 0.83) [16 (link)]. The scale in the present study also shows a good internal consistency (alpha = 0.88).
Coelho A., Kendir C., Barrenho E., Klazinga N., Paiva C., Abreu de Sousa J., Gonçalves-Monteiro S., Redondo P., Bastos A., Nogueira A., Guedes F.B., Costa A.S, & Gaspar T. (2023). Patient-Reported Outcomes and Experiences Assessment in Women with Breast Cancer: Portuguese Case Study. International Journal of Environmental Research and Public Health, 20(4), 2931.
Full text: Click here
Publication 2023
Breast Cytokinesis Lumpectomy Malignant Neoplasm of Breast Patients Radiotherapy Seizures Specialists Thoracic Surgical Procedures
4
Unilateral Breast-Conserving Therapy
The OECD guidelines were followed to define the inclusion and exclusion criteria [11 ]. According to that, women aged 15 and over were included in the study who received unilateral BCT (lumpectomy). Women that received bilateral or recurrent surgery were excluded.
Coelho A., Kendir C., Barrenho E., Klazinga N., Paiva C., Abreu de Sousa J., Gonçalves-Monteiro S., Redondo P., Bastos A., Nogueira A., Guedes F.B., Costa A.S, & Gaspar T. (2023). Patient-Reported Outcomes and Experiences Assessment in Women with Breast Cancer: Portuguese Case Study. International Journal of Environmental Research and Public Health, 20(4), 2931.
Full text: Click here
Publication 2023
Lumpectomy Operative Surgical Procedures Woman
5
APBI Protocol for Early Breast Cancer
29 patients (30 plans due to one patient with bilateral disease) previously receiving supine APBI treatment for early stage breast cancer (stages 0-2) at our institution between 2019 and 2022 were utilized in this Institutional Review Board (IRB-1207033005) approved study. Nine patients (10 plans) were used to iteratively tune an optimization template and an independent 20 patient cohort was utilized to validate the template via automatic replanning without intervention or reoptimization. Seven patients met RAD 1802 inclusion criteria and were simulated and contoured according to trial protocol. Inclusion criteria consisted of age ≥ 50, estrogen receptor (ER) positive, and negative margins of at least 2mm for invasive histology or 3mm for ductal carcinoma in situ, carcinoma in situ, or T1 disease. Patients receiving neoadjuvant chemotherapy or having multifocal cancer, pure invasive lobular histology, surgical margins< 2mm, a lumpectomy cavity within 5mm of the body contour, or unclear cavity delineation on the planning scan were excluded. Additionally, patients with evaluation PTV (PTV_Eval) volumes exceeding 124cc were excluded based on fat necrosis observed by Timmerman et al. above this threshold (8 (link)). 23 patients were not included in the RAD 1802 study, but were simulated, contoured, and planned with the same methods and intent. For all patients, an isotropic 1cm gross tumor volume (GTV) expansion was utilized for clinical target volume (CTV) generation and an isotropic 3mm CTV expansion was utilized for PTV generation. PTV_Eval volumes were created by carving out the PTV at anatomical boundaries (i.e., lung, rib, chest wall, and 5mm from the skin). PTV_Eval volume ranged from 28.6cc to 217.9cc, with an average of 85.2cc. Patients were prescribed 30Gy in five fractions, with an average 98.3% of the PTV_Eval receiving 30Gy in the original clinical plans. Patient characteristics are summarized in Table 1.
Pogue J.A., Cardenas C.E., Cao Y., Popple R.A., Soike M., Boggs D.H., Stanley D.N, & Harms J. (2023). Leveraging intelligent optimization for automated, cardiac-sparing accelerated partial breast treatment planning. Frontiers in Oncology, 13, 1130119.
Full text: Click here
Publication 2023
Breast Carcinoma in Situ Dental Caries Estrogen Receptors Human Body Infantile Neuroaxonal Dystrophy Lumpectomy Lung Malignant Neoplasms Necrosis, Fat Neoadjuvant Chemotherapy Noninfiltrating Intraductal Carcinoma Patients Radionuclide Imaging Skin Staging, Cancer Surgical Margins Wall, Chest

Top products related to «Lumpectomy»

1
Rna later tissue stabilization solution by Thermo Fisher Scientific
RNA Later Tissue Stabilization Solution is a reagent designed to preserve the integrity of RNA in tissue samples. It immediately stabilizes and protects RNA from degradation, allowing for the reliable collection, transportation, and storage of samples prior to RNA extraction and analysis.
2
Intrabeam by Zeiss
Sourced in Germany
The Intrabeam is a compact, single-use radiation therapy device designed for the treatment of certain types of cancer. It delivers targeted, low-energy radiation directly to the tumor site during surgery, providing a precise and efficient treatment option. The Intrabeam's core function is to deliver localized radiation therapy to the affected area, helping to minimize damage to surrounding healthy tissue.
3
Spss version 25 by IBM
Sourced in United States, United Kingdom, Japan, Austria, Germany, Denmark, Czechia, Belgium, Sweden, New Zealand, Spain
SPSS version 25 is a statistical software package developed by IBM. It is designed to analyze and manage data, providing users with a wide range of statistical analysis tools and techniques. The software is widely used in various fields, including academia, research, and business, for data processing, analysis, and reporting purposes.
4
Sas v9 by SAS Institute
Sourced in United States, Austria, United Kingdom, Cameroon, Belgium, Israel, Japan, Australia, France, Germany
SAS v9.4 is a software product developed by SAS Institute. It is a comprehensive data analysis and statistical software suite. The core function of SAS v9.4 is to provide users with tools for data management, analysis, and reporting.
5
Aquilion lb by Toshiba
Sourced in Japan
The Aquilion LB is a computed tomography (CT) imaging system developed by Toshiba. It is designed to provide high-quality imaging for a variety of medical applications. The system uses advanced technology to capture detailed images of the body, which can be used by healthcare professionals for diagnosis and treatment planning.
6
Stata version 11 by StataCorp
Sourced in United States, Denmark, United Kingdom
STATA version 11 is a software package for statistical analysis, data management, and graphics. It provides a wide range of statistical tools and functions for researchers, analysts, and professionals in various fields. The core function of STATA version 11 is to perform advanced statistical analysis and modeling on data.
7
Rnalater solution by Thermo Fisher Scientific
Sourced in United States, Germany, Lithuania, United Kingdom, Canada, France, Japan, Israel, Australia, Spain, Switzerland, Sweden
RNAlater solution is a nucleic acid stabilization reagent that immediately stabilizes and protects RNA in fresh tissue samples. It preserves the RNA in tissues and cells, preventing degradation and allowing for reliable downstream analysis.
8
Stata software by StataCorp
Sourced in United States, United Kingdom, Denmark, Austria
Stata is a general-purpose statistical software package for data analysis, data management, and graphics. It provides a wide range of data manipulation, statistical, and graphical tools to help researchers and analysts effectively analyze and visualize data.
9
Nanozoomer by Hamamatsu Photonics
Sourced in Japan, United Kingdom, France, United States, Germany
The NanoZoomer is a high-performance digital slide scanner produced by Hamamatsu Photonics. It is designed to digitize microscope slides with high-resolution imaging capabilities.

More about "Lumpectomy"

Lumpectomy, also known as breast-conserving surgery or partial mastectomy, is a surgical procedure used to treat early-stage breast cancer.
During this procedure, a small portion of the breast tissue containing the tumor or abnormality is removed, while the majority of the breast is left intact.
This approach aims to preserve the shape and appearance of the breast, offering a less invasive alternative to a full mastectomy.
The procedure typically involves the use of imaging techniques, such as mammography or ultrasound, to locate the tumor or abnormality within the breast.
Once the target area is identified, the surgeon will make an incision and remove the affected tissue, along with a small margin of healthy tissue surrounding it.
This helps ensure that all cancerous cells are removed while minimizing the impact on the breast's overall appearance.
Lumpectomy may be followed by radiation therapy, which can help reduce the risk of cancer recurrence.
The RNAlater tissue stabilization solution is sometimes used to preserve the excised tissue samples for further analysis, such as with the NanoZoomer digital pathology system.
Patients who undergo lumpectomy often experience a better quality of life compared to those who undergo a full mastectomy, as the procedure helps maintain the breast's natural shape and appearance.
The INTRABEAM Intraoperative Radiotherapy System is an innovative technology that can be used during lumpectomy to deliver targeted radiation therapy directly to the tumor site, potentially reducing the need for external beam radiation therapy.
Data analysis software, such as SPSS version 25, SAS v9.4, STATA version 11, and the Stata software, can be utilized to evaluate the outcomes and efficacy of lumpectomy procedures, allowing researchers and healthcare providers to optimize treatment protocols and improve patient care.